IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company ...

JPMorgan upgraded IGM Biosciences (IGMS) to Neutral from Underweight without a price target The firm says that with the company announcing ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December ...

IGM Biosciences (IGMS – Research Report) received a Hold rating and a $2.00 price target from Jefferies analyst Roger Song today. The company’s ...

IGM Biosciences shares dived 69% in premarket trading a day after the company said it would halt development of two of its treatments. Shares were trading around $1.94. The stock is up 1.5% on the ...

IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...